Asia Tech Wire (Oct 10) -- Eli Lilly and Company announced Wednesday the appointment of Thomas Fuchs as the company's first chief AI officer, effective October 21, 2024.

In this role, Fuchs will provide vision, strategic direction and overall leadership of AI initiatives across Lilly, including drug discovery, clinical trials, manufacturing, commercial activities and internal functions, the U.S. pharmaceutical company said in a statement.

Lilly said, "He will also identify, build and manage AI and machine learning solutions to help Lilly provide medicines to patients around the world."

Prior to joining Lilly, Fuchs served as the dean and inaugural department chair for AI and Human Health at Mount Sinai, director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy professor for AI and computational pathology at the Icahn School of Medicine at Mount Sinai.